EKF Molecular Diagnostics' PointMan DNA-enrichment technology reliable and extremely sensitive detection of cancer-related mutations. Fully compatible with industry standard instruments and DNA extraction methods, it is highly specific and efficient in amplifying the target sequence, while simultaneously suppressing amplification of the wild-type.
The resulting sample is effectively enriched for the mutation, providing industry-leading sensitivity across a wide variety of sample types, including whole blood.
PointMan’s ability to enrich low-level DNA mutations from whole blood is the focus of an ongoing collaboration between EKF Molecular Diagnostics and the Institute of Life Sciences at Swansea University. Recent preliminary results from a study of samples archived in the Wales Cancer Bank, have demonstrated that PointMan technology could enable non-invasive blood based testing and reduce the need for tumour biopsies for cancer patient mutation status assessment.
For more information, visit www.ekfdiagnostics.com
